Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

CLL: early-phase trial registry

3 of 9 indexed CLL trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 3 currently recruiting · #1,916 of 28,707 conditions by registered trial count

CLL: 9 US clinical trials tracked, 3 recruiting.

CLL is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is BeOne Medicines, running 2 of these trials.

Enrollment posture brief

Registry condition cll

OPEN 3 | RECR 33% | LATE 3 | EARLY 6 | RANK #1916 | SPON 2

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%CLL (this)33%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near CLL

CLL lists 3 open slots (33% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for CLL on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. CLL is recruiting below its size-band peers.

    3 of 9 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates CLL research.

    BeOne Medicines accounts for 2 of 9 trials (22.2%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Most CLL trials plan to enrol fewer than 100 people.

    Median target enrolment is 40 among the 9 trials that report a genuine target (sentinel values excluded). 6 of those (66.7%) plan for fewer than 100 participants.

  4. CLL research is mostly interventional.

    9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 23Phase 33

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 3 735 participants

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

Merck Sharp & Dohme

NCT05947851

RECRUITING Phase 3 250 participants

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

BeOne Medicines

NCT06846671

RECRUITING Phase 2 22 participants

Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

Zulfa Omer

NCT07108998

ACTIVE NOT RECRUITING Phase 3 652 participants

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

BeOne Medicines

NCT06073821

ACTIVE NOT RECRUITING Phase 1 56 participants

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

BeiGene

NCT06697184

ACTIVE NOT RECRUITING Phase 1 20 participants

Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL

University of Chicago

NCT03283137

COMPLETED Phase 1 40 participants

Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia

Genta Incorporated

NCT00021749

COMPLETED Phase 2 23 participants

Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)

M.D. Anderson Cancer Center

NCT01168921

COMPLETED Phase 2 16 participants

Allogeneic Transplantation From Related Haploidentical Donors

Stanford University

NCT00185692

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 3
Phase 3 3

Top Sponsors

Named interventions

Most-linked intervention names on CLL records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Venetoclax Drug
3 trials
Sonrotoclax Drug
2 trials
Zanubrutinib Drug
2 trials
Oblimerson sodium, G3139 Drug
1 trials
Anti-Thymocyte Globulin Drug
1 trials
non-myeloablative hematopoietic cell transplantation Procedure
1 trials
TGR-1202 Drug
1 trials
Idelalisib Drug
1 trials

US sites by state

Facility locations filed on CLL trials. A trial with sites in several states counts in each.

Florida 4 trials
California 4 trials
Texas 3 trials
New York 3 trials
Washington 2 trials
Oregon 2 trials
Ohio 2 trials
Missouri 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this CLL page

9 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This CLL condition card totals 9 registered trials; most-linked intervention Venetoclax; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.